LCM
NUVB icon

LCM Capital Management’s Nuvation Bio NUVB Stock Holding History

LCM Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.2K Hold
15,000
– – 0.04% 119
2026
Q1 		$64.3K Hold
15,000
– – 0.03% 106
2025
Q4 		$134K Sell
15,000
-500
-3% -$3.1K 0.07% 105
2025
Q3 		$57.4K Buy
15,500
+3,500
+29% +$9.54K 0.03% 105
2025
Q2 		$23.4K Buy
+12,000
New +$25K 0.01% 104

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LCM Capital Management's NUVB Position: Q2 2026 in Review

LCM Capital Management held its Nuvation Bio (NUVB) position steady in Q2 2026 at 15,000 shares worth $85.2K. The position accounts for 0.04% of the portfolio, ranked #119.

LCM Capital Management first reported a position in NUVB in Q2 2025 and has held it in 5 quarters since. The position peaked at $134K in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • LCM Capital Management held 15,000 shares of Nuvation Bio worth $85.2K as of Q2 2026.
  • LCM Capital Management left its Nuvation Bio share count unchanged in Q2 2026.
  • Nuvation Bio made up 0.04% of LCM Capital Management's portfolio in Q2 2026, its #119 holding.
  • LCM Capital Management first reported a position in Nuvation Bio in Q2 2025 and has held it in 5 quarters since.
  • LCM Capital Management's Nuvation Bio position peaked at $134K in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on LCM Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.